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Background and Aims: There is little agreement on the nomenclature and description
of Crohn’s disease (CD) lesions that can be found in the small and large bowel using
capsule endoscopy (CE). We performed a systematic review to identify mucosal lesions
that have been described using CE in CD, in both the small bowel and colon, with the
aim to make propositions to homogenize such descriptions.
Methods: A systematic literature search was conducted using Embase, Medline
(OvidSP), and Cochrane Central on August 6, 2019. Clinical studies providing
nomenclature and descriptions for small bowel and colonic inflammatory lesions using
CE in CD were selected for data collection.
Results: In total, 851 articles were included for abstract screening out of which 219 were
analyzed for full-text review. Twenty-two articles were selected for data extraction. Seven
items, accompanied by clear descriptions, were found for the small bowel: i.e., ulcer,
erosion, aphthoid lesion, edema, fissure, cobblestone appearance, and villous atrophy.
No studies were found describing inflammatory items using CE in colonic CD.
Conclusions: The most frequently described CD lesions using CE were ulcers and
erosions. Subjective interpretation of CE inflammatory findings plays an important role.
Based on our findings, a range of suggestions regarding items and descriptions is made
that might form the basis of a pan-enteric CE activity index.
Keywords: inflammatory bowel diseases, Crohn’s disease, capsule endoscopy, intestine, small/diagnostic
imaging, intestine, small/pathology
INTRODUCTION
Capsule endoscopy (CE) provides a reliable and non-invasive method to visualize the entire
gastrointestinal tract. CE has a diagnostic yield of 50% to detect mucosal lesions in the small
bowel of Crohn’s disease (CD) patients (1). However, little agreement exists on how to describe
such mucosal lesions using CE in CD. Capsule Endoscopy Structured Terminology (CEST) has
been designed and published by international societies trying to seek consensus in interpreting and
reporting small bowel CE examinations (2). Despite standardized terminology, descriptions vary
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considerably throughout different studies, and also interpretation
of these findings varies widely among different observers.
Furthermore, criteria for small bowel CE-based activity
assessment in CD vary considerably between different studies.
The two available and validated endoscopic activity indices to
assess small bowel CD activity [Capsule Endoscopy Crohn’s
Disease Activity Index (CECDAI) (3) and Lewis Score (LS) (4)]
both rely on three parameters: inflammatory lesions, disease
extension, and presence of strictures. In the LS, differentiation of
ulcers from mucosal breaks, erosions and aphthoid lesions have
been eliminated in order to develop a more user-friendly activity
index. Moreover, this score provides an accurate description
of inflammatory items (villous edema and ulcer). In contrast,
the CECDAI does not provide item descriptions but grades
findings from mild to severe and separates mucosal breaks into
different sizes. Both activity scores contain inflammatory lesions
with clinical significance according to a CE consensus meeting.
However, only the LS provides clear descriptions for each
item. Nevertheless, proposed descriptions were not consensually
agreed upon.
On the other hand, validated scoring systems to assess
colonic CD activity with CE are lacking. Hence, CE cannot be
recommended yet to replace conventional colonoscopy in CD
(5). In the past years, several studies showed that CE, using the
second-generation colon capsule, is a safe and feasible tool to
assess inflammatory activity in the small and large bowel (6–
10). However, one study demonstrated an underestimation of the
total ulcerated surface in the colon mainly because of insufficient
bowel cleansing techniques compared to conventional endoscopy
(6). Moreover, evidence suggests that CE is a useful technique
to monitor post-operative CD patients (11). Nevertheless, all
available CE studies used endoscopic activity indices, and no
specific terminology for colonic findings has been proposed
using CE.
In the treat-to-target era, where mucosal healing is an
important treatment goal in CD, development of an activity
index to assess the entire gastrointestinal tract, including the
colon, is warranted. Recently, a pan-enteric index (CECDAIic)
has been created demonstrating its usefulness in CD (12, 13). This
particular CE activity score is based on the CECDAI and gives
a comprehensive view of the entire intestinal tract but does not
provide a clear description of inflammatory lesions.
Hence, validated scoring systems for pan-enteric CE that are
accompanied by clear descriptions of items are lacking. As a
first step, all CD-related mucosal lesions that have been reported
in the literature should be characterized. Next, a consensus
meeting consisting of CE experts should find agreement in the
nomenclature and how to describe these items. As a final step,
this might result in the development of a pan-enteric CE activity
index. The development of such an index will likely decrease
intra- and inter-observer disagreement.
Currently, scarce consensus exists on how to describe CD
lesions detected by CE. In that regard, a Delphi consensus
meeting took place consisting of small bowel CE experts. This
working group proposed a set of items, together with clear
descriptions, on how to describe small bowel CD lesions using
CE (14), based on the LS and CECDAI.
With the aim of contributing to a uniform report of
mucosal lesions, we performed a systematic review to identify
all descriptions for mucosal inflammatory lesions using CE in
the small and large bowels in CD patients, in order to make
recommendations that might form the basis of a pan-enteric CE
activity index.
METHODS
A systematic literature search was performed using the
following databases on August 6, 2019: MEDLINE, EMBASE,
and Cochrane library. The search strategy can be found
as Supplementary Material. Two authors (MM and AS)
independently screened all the articles by title and abstract, and
when included by at least one of the authors for full-text revision
the full article was analyzed. Any disagreements were resolved
by discussion with a third author (ML) followed by a consensus
meeting (ML, MM, and AS).
Study selection was carried out according to PICOS criteria
for including and excluding studies. The inclusion criteria
were as follows: description of CE items in the small bowel
and/or the colon in patients with known or suspected CD
who underwent CE for different indications [i.e., diagnosis
(suspicion of CD) or staging, assessment of disease activity,
or mucosal healing (in patients with known CD)]. Exclusion
criteria were as follows: (1) provide CE items without description;
(2) sample size <10CD patients; (3) editorials, letters, review
articles, meta-analyses, guidelines, meeting abstracts, and non-
fully published data; (4) duplicated studies; and (5) other
than English language. After the full-text selection, every
CE item with its description was collected. Finally, we
checked if the terminology was in line with international
recommendations (2). We decided to exclude articles with
<10CD patients as a cut-off to assume the experience in
CE in inflammatory bowel diseases. In that same line, we
also checked if the study provided data regarding inter-
and intra-observer agreement of each described item between
CE observers.
RESULTS
The literature search identified 1,285 records. Three additional
records were identified through other sources. After removing
duplicates, a total of 854 records were screened for inclusion.
After screening titles and abstracts, 219 reports were selected for
full-text review. After full-text review, 22 studies were included in
the data collection process. A flowchart of the selection process is
shown in Figure 1.
Item Description Data
The selected studies provided an item description of the
mucosal lesions with assumed clinical relevance in CD. All
papers provided a priori specified item description before study
performance. These definitions are shown in Table 1.
We found in total seven mucosal lesions with different
descriptions. All items referred to small bowel CD lesions.
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FIGURE 1 | Flow diagram of the study selection process.
The most frequently described items were ulcer (4, 16–
28, 30, 32–35) and erosion (16, 17, 19–24, 26, 29, 33–35).
Both definitions are characterized by a central mucosal defect
with surrounding focal erythema and are distinguished from
each other based on their size and depth of the defect.
Different terminology has been used concerning each feature:
crater, white lesion, mucosal break, pale lesion, white/yellow
base, loss of mucosal substance, red/pink collar, or red
rim. Esaki and colleagues (35) also distinguished ulcers and
erosions according to shape (i.e., oval, circular, longitudinal,
and irregular).
For aphthoid lesion, three different definitions were found
(15, 21, 27, 29, 33). These are comparable to erosion
descriptions, specifying its superficiality or small size. The
validation study of the well-known LS provided the description
for the item edema, characterized by equal or greater villous
width when compared to villous height (4). To describe
cobblestone pattern, two definitions have been used that take
into account the presence and disposition of longitudinal
ulcers (27, 31). One single definition has been provided for
fissure (27) and villous atrophy (20). We did not identify
any description regarding colonic lesions. With reference to
the CEST standardized nomenclature, all terms are included
in these international recommendations except for fissure and
cobblestone pattern.
Inter- and Intra-observer Agreement
Assessment for Each Described Lesion
Two studies assessed agreement between CE observers regarding
lesion identification and description (4, 35). These results are
summarized in Table 2. Kappa statistics (k) were used to measure
inter-rater reliability, with values ranging from 0 (absence of
agreement) to 1 (perfect agreement). They interpreted values
<0.20 as slight, 0.21–0.40 as fair, 0.41–0.60 as moderate, 0.61–
0.80 as good, and >0.81 as excellent agreement.
Esaki and collaborators (35) distinguished ulcers and erosions
according to four shapes. They evaluated the inter-observer
agreement between one expert capsule endoscopist and three
observers, analyzing small bowel CE results obtained from
25CD patients. A slight to moderate agreement was found
for oval and longitudinal ulcers, fair to good agreement for
irregular ulcers, and fair to moderate agreement for circular
ulcers. The authors detected slight to moderate agreement for
overall erosion forms. The intra-observer agreement for the
expert capsule endoscopist was fair, good, moderate, and good
for oval, longitudinal, irregular, and circular ulcers, respectively.
Intra-observer agreement was moderate for all erosion shapes.
Gralnek and colleagues (4) found moderate agreement
for villous edema and good agreement for ulcer detection
between four CE observers who analyzed 34 CE studies from
CD patients.





































TABLE 1 | Nomenclature used to specify inflammatory-related findings for CE in small bowel CD and the different descriptions given to each of them.
Authors Nomenclature and description




a white central area
Mow et al. (16) White lesions within a crater and
with surrounding erythema




White lesions within a crater and
with surrounding erythema




Aphtous ulcer: white center and
a red halo around it




Mucosal breaks with white or
yellow bases surrounded by red
or pink collars.
Villous width is equal




White lesions within a crater and
with surrounding erythema




White lesions within a crater and
with a surrounding erythema






Pale lesion within a crater
representing a visible loss of
mucosal substance.
Superficial and pale mucosal
break surrounded by a red rim.
Superficial and pale
mucosal break surrounded
by a red rim.
Mehdizadeh
et al. (22)
White lesions within a crater and
with surrounding erythema




White lesions within a crater
with surrounding erythema
Small superficial white lesions,
even with surrounding erythema
Di Nardo et al.
(24)
White lesions within a crater
with surrounding erythema
Small superficial white lesions,
even with surrounding erythema
Koulaouzidis
et al. (25)
Any pale or yellow-based
mucosal break surrounded by a
red or a pink collar
Esaki et al. (26) Whitish crater surrounded by
mucosal erythema presumably
measuring over 5mm
Superficial whitish lesion with




Pale lesion within a crater




by a red rim
Longitudinal ulcers Connected longitudinal
and transversal fissures
Höög et al. (28) Mucosal breaks with white or
yellow bases surrounded by red
or pink collars.
Kono et al. (29) Small mucosal breaks of ≤3mm Small mucosal breaks of
≤3mm





















































































































































































































































































































































































































































































































































TABLE 2 | Studies assessing CE readers’ agreement in relation to particular small






































Furthermore, four studies assessed observer agreement with
regard to global small bowel inflammation by means of different
small bowel CD scoring but not for any particular lesion (4, 17,
21, 31).
DISCUSSION
Currently, there is no consensus on how to describe small bowel
and colonic lesions that can be found with CE in CD patients. We
aimed to identify all mucosal lesions that have been described,
both in the small bowel and in the colon, seeking common points
in terms and descriptions to homogenize definition of mucosal
lesions. Studies that lacked a clear description of mucosal lesions
were excluded.
The most frequently described items related to inflammation
in the small bowel of CD patients were ulcers and erosions.
Both items are distinguished based on size or depth of the
lesion, expressed by the presence of a crater or mucosal break.
We propose to avoid this distinction based on size estimation,
because objective measurement tools in CE are lacking and
CE layout in relation to lesions when assessing a video may
determine its interpretation. It should also be noted that the term
mucosal break could lead to confusion, since it is generally used
as a way to describe loss of mucosal substance, but some authors
use it as a way to establish a deeper mucosal defect.We encourage
to avoid this description of deep mucosal defect and propose to
use other descriptors in that regard, such as crater. Moreover, the
shape-based description approach by Esaki and coworkers could
be counter-productive, because this is a subjective evaluation that
might result in intra- and inter-observer disagreement.
With conventional endoscopy, an aphthoid lesion has been
traditionally considered different from an erosion, since an
aphthoid lesion has been seen as a flat or elevated lesion
and an erosion as an excavated lesion covered by fibrin
material. However, an aphthoid lesion is not included in the
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recommendations for endoscopy terminology of the World
Endoscopy Organization (36). In the CEST, these two terms
are classified separately, and the term aphthoid lesion is also
considered an excavated lesion. Moreover, the CECDAI includes
both terms with no attribute assessment. Therefore, we propose
that these two terms could be used indistinctly.
The term edema is included in the CEST as a mucosal feature
and is used in the two available validated activity indices, but
only the LS validation study provides a description, testing its
reproducibility with moderate inter-observer agreement but with
no intra-observer agreement evaluation. Since the LS has been
widely accepted for small bowel assessment in CD, few authors
have insisted on changing this item description.
Fissure and cobblestone pattern are not included in the CEST.
Halling et al. use the term fissure to describe longitudinal ulcers,
and, due to its redundancy, we think it should be avoided. The
cobblestone pattern definition provided by Urgesi and colleagues
seems to be more accurate than the one provided by Halling and
coworkers, since the Japanese criteria for CD diagnosis proposes
the definition only by the presence of longitudinal ulcers
when diagnosing CD (37), for both ileal and colonic diseases.
Otherwise, it has always been related to a severe affectation, and
it rarely appears in other inflammatory bowel diseases. As for
colonoscopy, well-known activity indices (SES-CD and CDEIS)
do not include cobblestone pattern as a diagnostic criteria by
itself; hence, we think it should be avoided for inclusion in small
bowel disease CE index.
We found one single definition of villous atrophy. The CEST
uses the term atrophy when referring to mucosal aspect, not
to villi, and applies the labels of shape and color concerning
villi appearance. A Delphi consensus meeting (14) proposed to
describe the absence of villi with the term denudation, with no
reference to mucosal atrophy. Nevertheless, the group describing
the LS eliminated denuded mucosa, because it was considered an
item unable to be judged objectively and with perceived lack of
clinical significance.
No studies were found that described colonic lesions with
CE in CD. Most of these studies used endoscopic activity
indices to score disease activity. The CECDAIic pan-enteric score
validation study extrapolated to colon the inflammatory indicator
used in the CECDAI for small bowel disease (12), with no colonic
lesions description. Future studies are warranted using colon CE
and pan-enteric CE in CD patients in order to better characterize
mucosal lesions that can be found in the whole intestine. It will
be of great importance to reach consensus between experts in
characterizing mucosal lesions to improve agreement between
readers using CE in CD patients. Additionally, these will help in
better CE training, optimization of the learning curve, and broad
implementation of CE in clinical practice.
Here, we mainly focus on inflammatory item description,
working toward a more objective nomenclature and description.
Of note, we did not analyze items that were related to stenosis,
because its general definition implies a delay or withholding of
CE rather than describing the mucosal pattern, even if it may
be related with deep ulcers or edematous tissue. Likewise, we
did not investigate studies focusing on the clinical relevance of
mucosal lesions that can be detected by CE. Theoretically, the
lesions to be considered suitable for scoring should contribute to
clinical symptoms, correlate with endoscopic activity scores and
with biological markers, and have a good rate of responsiveness
on treatment outcomes. Beyond this point, the general line in the
practice is to describe clinical relevance once different items have
been included in a global score. The LS and the CECDAI both
demonstrated its usefulness in diagnosing CD (38, 39) as well
as staging (40) and monitoring CD patients (41, 42). Moreover,
correlations between these scores and inflammatory biomarkers
(fecal calprotectin and C-reactive protein) have been shown
(43, 44). Likewise, the above-cited expert Delphi consensus about
nomenclature and description of small bowel lesions only took
into account small bowel items that were part of the LS and
CECDAI. As stated by the authors, this consensus meeting
did not assess the clinical relevance of such lesions. We are
also aware that we may have left behind information regarding
clinical relevance in studies not providing a clear description of
mucosal lesions.
In conclusion, this robust systematic review identifies mucosal
lesions that have been described using CE in CD in the small
and large bowels. Personal interpretation plays an important role
in describing these mucosal lesions. Here, we make suggestions
to homogenize description of mucosal lesions detected by CE
in CD. We suggest that to avoid ulcerative lesion distinction
based on size or shape, the terms erosion and aphtoid lesion
may be used indistinctly, the term mucosal crater should be
avoided when describing an ulcer since it may be confusing,
and the items fissure and cobblestone pattern might be of
unnecessary redundancy and should be avoided. This manuscript
may serve as a starting point to reach consensus between experts
and might contribute to the development of a pan-enteric CE
activity index.
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